Search clinical trials for: Linagliptin (DPP4)

Total 900 results

JW Pharmaceutical

Recruiting

Glycemic Variability of Combination Therapies in T2DM

Type 2 Diabetes Mellitus (T2DM)

South Korea
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Bahria University

Enrolling by invitation

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Type 2 Diabetes Mellitus

Pakistan
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Mayo Clinic

Completed

Anti-Diabetic Medications to Fight PD and LBD

Parkinson Disease | Lewy Body Dementia

United States
Chinese PLA General Hospital

Completed

Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

Coronary Angiography | Dipeptidyl Peptidase 4
JW Pharmaceutical

Completed

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (ACACIA)

Type 2 Diabetes

Korea, Republic of
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (TRED)

Type 2 Diabetes

China
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Shanghai 10th People's Hospital

Completed

Non-alcoholic Fatty Liver Disease and Its Treatment

NAFLD
University of Dundee

Completed

Study of Sulphonylurea Synergy With DPP4 Inhibitors (SSS)

Type 2 Diabetes

United Kingdom
First Affiliated Hospital Xi'an Jiaotong University

Unknown

Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell (TOND)

Type 2 Diabetes Mellitus

China
Khoo Teck Puat Hospital

Completed

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Type II Diabetes in Subjects BMI 27 to 32

Singapore
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Kaiser Permanente
Patient-Centered Outcomes Research Institute; Henry Ford Health System; HealthPartners... and other collaborators

Completed

Comparison of Type 2 Diabetes Pharmacotherapy Regimens (ON TARGET DM)

Cardiovascular Diseases | Type 2 Diabetes Mellitus

United States
Johns Hopkins Bloomberg School of Public Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Pilot Trial of a Novel Cooking Skills Intervention (DPPCooks) to Prevent Diabetes (DPPCooks)

Pre-diabetes

United States
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
SINA Health Education and Welfare Trust
Horizon Pharmaceutical Pvt Ltd

Completed

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Hypoglycemic Agents | Empagliflozin

Pakistan
The Catholic University of Korea

Completed

DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

Diabetes Mellitus

Korea, Republic of
Fundación Pública Andaluza para la gestión de la...
AstraZeneca

Completed

Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

Diabetes Mellitus, Type 2

Spain
Stanford University
Patient-Centered Outcomes Research Institute; San Jose State University

Completed

A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians

Diabetes Mellitus, Type 2 | Metabolic Syndrome | Insulin Resistance

United States
Fundación para la Investigación del Hospital Clínico...
Instituto de Salud Carlos III; European Union Next Generation

Active, not recruiting

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (EPHIC-DIA2)

Diabetes Mellitus Type 2

Spain
University of British Columbia
Merck Sharp & Dohme LLC

Terminated

Effect of Sitagliptin on Graft Function Following Islet Transplantation

Islet Transplantation

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Dong Wha Pharmaceutical Co. Ltd.

Completed

the Pharmacokinetic Profiles of Linagliptin With DW1029M (PLID)

Healthy

Korea, Republic of
Kaiser Permanente

Completed

Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System

Diabetes

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC (Neo-CD)

Colorectal Cancer

China
Chung-Ang University

Unknown

The Effect of DPP4 Inhibitor on Vasclular Healing

Diabetes Mellitus, Type 2 | Acute Coronary Syndrome

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

United States, Estonia, Germany, Latvia, Spain, United Kingdom
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Healthy
Yanbing Li

Not yet recruiting

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes (COLOR-REAL)

Type 2 Diabetes

China
University of British Columbia

Terminated

Sitagliptin in Cystic Fibrosis-Related Diabetes

Cystic Fibrosis

Canada
Institute for Clinical Effectiveness, Japan

Completed

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial (REASON)

Coronary Disease | Diabetes Mellitus | Dipeptidyl-Peptidase 4 Inhibitors | LDL Cholesterol | Glycosylated Hemoglobin

Japan
Evidem Consultores SL
Boehringer Ingelheim; Merck Serono International SA; European Commission

Unknown

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study (ePREDICE)

PreDiabetes

Spain
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Renal Insufficiency
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Lovoria Williams
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

Diabetes

United States
The University of Texas Medical Branch, Galveston

Withdrawn

Healthy Hearts: Leveraging the Diabetes Prevention Program to Decrease Health Disparities in Women of Reproductive Age (HH)

Hypertension | Prediabetic State | Overweight or Obesity | Gestational Weight Gain
Royal Devon and Exeter NHS Foundation Trust
King's College London; Newcastle University; NHS Tayside; University of Dundee; University... and other collaborators

Completed

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. (TriMaster)

Type 2 Diabetes

United Kingdom
Albert Einstein College of Medicine
New York Presbyterian Hospital; Chinese American Independent Practice Association... and other collaborators

Completed

Chinese Diabetes Prevention Program (Chinese DPP)

Prediabetes

United States
University Hospital, Gentofte, Copenhagen

Completed

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

Type2 Diabetes

Denmark
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Hypertension | Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
Boehringer Ingelheim

Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2

Belgium, Canada, France, India, Italy, Korea, Republic of, Malaysia, Netherlands, Spain
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States

Search clinical trials for: Linagliptin (DPP4)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations